Your browser doesn't support javascript.
loading
Liquid Biopsy for Detection of Pancreaticobiliary Cancers by Functional Enrichment and Immunofluorescent Profiling of Circulating Tumor Cells and Their Clusters.
Gaya, Andrew; Rohatgi, Nitesh; Limaye, Sewanti; Shreenivas, Aditya; Ajami, Ramin; Akolkar, Dadasaheb; Datta, Vineet; Srinivasan, Ajay; Patil, Darshana.
Afiliação
  • Gaya A; Department of Clinical Oncology, Cromwell Hospital, London SW5 0TU, UK.
  • Rohatgi N; Department of Medical Oncology, Fortis Memorial Research Institute, Gurugram 122002, HR, India.
  • Limaye S; Department of Medical and Precision Oncology, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai 400004, MH, India.
  • Shreenivas A; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Ajami R; Department of Oncology, The Royal Free Hospital, London NW3 2QG, UK.
  • Akolkar D; Department of Research and Innovation, Datar Cancer Genetics, Nasik 422010, MH, India.
  • Datta V; Department of Research and Innovation, Datar Cancer Genetics, Nasik 422010, MH, India.
  • Srinivasan A; Department of Research and Innovation, Datar Cancer Genetics, Nasik 422010, MH, India.
  • Patil D; Department of Research and Innovation, Datar Cancer Genetics, Nasik 422010, MH, India.
Cancers (Basel) ; 16(7)2024 Apr 02.
Article em En | MEDLINE | ID: mdl-38611078
ABSTRACT
Circulating tumor cells (CTCs) have historically been used for prognostication in oncology. We evaluate the performance of liquid biopsy CTC assay as a diagnostic tool in suspected pancreaticobiliary cancers (PBC). The assay utilizes functional enrichment of CTCs followed by immunofluorescent profiling of organ-specific markers. The performance of the assay was first evaluated in a multicentric case-control study of blood samples from 360 participants, including 188 PBC cases (pre-biopsy samples) and 172 healthy individuals. A subsequent prospective observational study included pre-biopsy blood samples from 88 individuals with suspicion of PBC and no prior diagnosis of cancer. CTCs were harvested using a unique functional enrichment method and used for immunofluorescent profiling for CA19.9, Maspin, EpCAM, CK, and CD45, blinded to the tissue histopathological diagnosis. TruBlood® malignant or non-malignant predictions were compared with tissue diagnoses to establish sensitivity and specificity. The test had 95.9% overall sensitivity (95% CI 86.0-99.5%) and 92.3% specificity (95% CI 79.13% to 98.38%) to differentiate PBC (n = 49) from benign conditions (n = 39). The high accuracy of the CTC-based TruBlood test demonstrates its potential clinical application as a diagnostic tool to assist the effective detection of PBC when tissue sampling is unviable or inconclusive.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article